TAYTULLA
DEAD

Serial Number

86847094

Owner

Forest Laboratories, LLC

Filing Date

Dec 11, 2015

Add to watchlist:

No watchlists yet
View on USPTO

TAYTULLA Trademark

Serial Number: 86847094

TAYTULLA is a trademark filed by Forest Laboratories, LLC on December 11, 2015. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Forest Laboratories, LLC (97 trademarks)

909 Third Avenue
New York, NY 10022

Entity Type: 16

Trademark Details

Filing Date

December 11, 2015

Registration Date

Not Registered

Published for Opposition

May 31, 2016

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Feb 27, 2017 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 27, 2017 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 26, 2016 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 31, 2016 NPUB
PUBLISHED FOR OPPOSITION
May 31, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 11, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 26, 2016 PREV
ASSIGNED TO LIE
Apr 19, 2016 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 2, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 1, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 1, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 1, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 1, 2016 CNEA
ASSIGNED TO EXAMINER
Mar 29, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 16, 2015 NWOS
NEW APPLICATION ENTERED
Dec 15, 2015 NWAP